Lamlique is a drug owned by Azurity Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 14, 2045. Details of Lamlique's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12605388 | Lamotrigine Salts, Co-Crystals, And Compositions |
Feb, 2045
(18 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but
Lamlique is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Lamlique's family patents as well as insights into
ongoing legal events
on those patents.
Lamlique's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Lamlique's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 14, 2045 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Lamlique Generics:
There are no approved generic versions for Lamlique as of now.
About Lamlique
Lamlique is a drug owned by Azurity Pharmaceuticals Inc. Lamlique uses Lamotrigine Hemifumarate as an active ingredient. Lamlique was launched by Azurity in 2026.
Approval Date:
Lamlique was approved by FDA for market use on 25 September, 2026.
Active Ingredient:
Lamlique uses Lamotrigine Hemifumarate as the active ingredient. Check out other Drugs and Companies using Lamotrigine Hemifumarate ingredient
Dosage:
Lamlique is available in suspension form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 25MG BASE/ML | SUSPENSION | Prescription | ORAL |
| EQ 5MG BASE/ML | SUSPENSION | Prescription | ORAL |